サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1795298

オンボディ・インジェクターの世界市場

On-Body Injectors

出版日
ページ情報
英文 177 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.55円
オンボディ・インジェクターの世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 177 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

オンボディ・インジェクターの世界市場は2030年までに70億米ドルに達する見込み

2024年に41億米ドルと推定されるオンボディ・インジェクターの世界市場は、2024年から2030年にかけてCAGR 9.5%で成長し、2030年には70億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである電子インジェクターは、CAGR 11.1%を記録し、分析期間終了までに47億米ドルに達すると予想されます。機械式インジェクターセグメントの成長率は、分析期間でCAGR 6.7%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR 9.1％で成長予測

米国のオンボディ・インジェクター市場は2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.9%と7.8%と予測されています。欧州では、ドイツがCAGR約7.4%で成長すると予測されています。

世界のオンボディ・インジェクター市場- 主要動向と促進要因のまとめ

なぜオンボディ・インジェクターがドラッグデリバリーを変革するのか？

オンボディ・インジェクター（OBI）は、大容量の生物製剤や薬剤を制御された期間にわたって皮下投与するように設計されたウェアラブルドラッグデリバリーシステムです。これらのデバイスは通常、腹部や腕に装着され、患者が自宅で治療を自己管理することを可能にし、病院での点滴や頻繁な臨床への依存を軽減します。オンボディ・インジェクターは、がん、自己免疫疾患、糖尿病など、定期的な投与が必要な慢性疾患に特に有用です。

患者中心の、低侵襲で利便性の高いドラッグデリバリーソリューションに対する需要の高まりにより、その採用が増加しています。OBIは、投与中に患者が積極的に関与することなく、最小限の不快感で投与を可能にすることで、より良い治療のアドヒアランスをサポートします。また、従来のプレフィルドシリンジや自動注射器では迅速に注入できない高粘度の生物製剤のデリバリーも可能です。このウェアラブル注射器へのシフトは、遠隔治療や在宅治療におけるより広範な動向と一致しています。

デバイスの設計と技術の進歩はどのようにオンボディ・インジェクターを向上させているか？

技術革新は、人間工学、安全性、機能性の向上を通じて、次世代のオンボディ・インジェクターを形成しています。最新のOBIは、プレフィルド薬剤リザーバー、自動針挿入・引き込み機構、患者を誘導する音声または視覚インジケータを備えています。機器によってはデジタル接続が可能なものもあり、使用データをヘルスケアプロバイダーに送信し、遠隔モニタリングや治療管理を行うことができます。

部品の小型化、皮膚接着剤の強化、圧力センサーとマイクロポンプの統合により、器具はより目立たなくなり、装着感も快適になっています。ドラッグデリバリーは現在、数分から数時間にわたってコントロールでき、最大5mL以上の投与が可能です。高粘度製剤との適合性も向上しており、以前は静脈内投与に限られていたモノクローナル抗体、ホルモン、長時間作用型治療薬の皮下投与が可能になっています。

どのような治療・市場動向がOBIの使用を拡大しているか？

慢性疾患の増加と生物学的製剤の承認が、OBIのような患者に優しいデリバリー・システムの需要を促進しています。腫瘍学では、ペグフィルグラスチムのような薬剤のオンボディデリバリーが外来患者ケアモデルを可能にし、通院による感染リスクを低減しています。関節リウマチやクローン病などの自己免疫疾患では、OBIによって、注射による疲労や移動の負担なしに定期的な生物学的製剤治療が可能になります。

製薬会社は、臨床試験や商業化計画にOBIを組み込んで、薬剤とデバイスの組み合わせ製品を共同開発するようになってきています。規制機関は、治療コンプライアンスを向上させるデバイスの役割を認識し、このような統合開発を奨励しています。さらに、支払者やヘルスケアシステムは、入院や輸液センターのコストを削減するため、在宅投与を支援しています。こうした動向は、OBIの役割をニッチな生物製剤からより広範な慢性疾患管理へと拡大しつつあります。

オンボディ・インジェクター市場の成長を促進する要因は何か？

オンボディ・インジェクター市場の成長は、いくつかの要因によってもたらされます。慢性疾患や生活習慣病の増加により、長期的なドラッグデリバリーソリューションに対する需要が高まっています。高濃度・高粘度薬剤を含む生物学的製剤の進歩により、ウェアラブルデリバリープラットフォームのニーズが高まっています。自己投与や在宅治療に対する患者の嗜好は、特に腫瘍学、免疫学、内分泌学においてOBIの採用を加速させています。機器の設計、安全性、デジタル統合における技術的改善が、規制当局の承認と市場浸透を後押ししています。さらに、ヘルスケアコストへの圧力とバリュー・ベース・ケアへのシフトが、製薬企業やデバイス企業に、治療の複雑性を軽減し、アドヒアランスを改善し、患者のQOLを高めるOBIへの投資を促しています。これらの要因が、ウェアラブル注射器開発と世界市場拡大の力強い勢いを支えています。

セグメント

タイプ（電子式注射器、機械式注射器）;疾患（糖尿病疾患、心血管疾患、神経疾患、免疫腫瘍疾患、その他の疾患）;エンドユーザー（病院・診療所エンドユーザー、外来手術センターエンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • AptarGroup Inc.
  • BD（Becton, Dickinson & Co.）
  • Coherus BioSciences, Inc.
  • Debiotech SA
  • E3D Elcam Drug Delivery Devices
  • Enable Injections
  • Gerresheimer AG
  • Insulet Corporation
  • LTS Lohmann Therapie-Systeme AG
  • Medtronic plc
  • Nemera
  • Roche（Accu-Chek）
  • Sanofi
  • ScPharmaceuticals（ScPharma）
  • Sensile Medical AG
  • SteadyMed Therapeutics
  • Stevanato Group
  • West Pharmaceutical Services, Inc.
  • Ypsomed AG

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP37566

Global On-Body Injectors Market to Reach US$7.0 Billion by 2030

The global market for On-Body Injectors estimated at US$4.1 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2024-2030. Electronic Injectors, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Mechanical Injectors segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.1% CAGR

The On-Body Injectors market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global On-Body Injectors Market - Key Trends & Drivers Summarized

Why Are On-Body Injectors Transforming Drug Delivery Practices?

On-body injectors (OBIs) are wearable drug delivery systems designed to administer large-volume biologics or medications subcutaneously over a controlled period. These devices are typically applied to the abdomen or arm and allow patients to self-administer treatments at home, reducing dependence on hospital-based infusions or frequent clinical visits. On-body injectors are particularly useful for chronic conditions that require regular dosing, such as cancer, autoimmune disorders, and diabetes.

Their adoption is rising due to growing demand for patient-centric, minimally invasive, and convenient drug delivery solutions. OBIs support better treatment adherence by allowing administration with minimal patient discomfort and without active engagement during delivery. They also enable delivery of high-viscosity biologics that cannot be injected rapidly with traditional prefilled syringes or autoinjectors. This shift toward wearable injectors aligns with broader trends in remote care and at-home therapeutics.

How Are Device Design and Technology Advancements Enhancing On-Body Injectors?

Technological innovation is shaping the next generation of on-body injectors through improved ergonomics, safety, and functionality. Modern OBIs feature prefilled drug reservoirs, automatic needle insertion and retraction mechanisms, and audible or visual indicators to guide patients through the process. Some devices offer digital connectivity, enabling transmission of usage data to healthcare providers for remote monitoring and treatment management.

Miniaturization of components, enhanced skin adhesives, and integration of pressure sensors and micro-pumps are making devices more discreet and comfortable to wear. Drug delivery can now be controlled over durations ranging from a few minutes to several hours, allowing administration of volumes up to 5 mL or more. Compatibility with high-viscosity formulations is also improving, enabling subcutaneous delivery of monoclonal antibodies, hormones, and long-acting therapeutics that were previously limited to intravenous routes.

What Therapeutic and Market Trends Are Expanding the Use of OBIs?

Growing prevalence of chronic diseases and biologic drug approvals is driving demand for patient-friendly delivery systems like OBIs. In oncology, on-body delivery of drugs such as pegfilgrastim is enabling outpatient care models and reducing infection risk from clinic visits. In autoimmune conditions such as rheumatoid arthritis and Crohn’s disease, OBIs allow regular biologic therapy without injection fatigue or travel burden.

Pharmaceutical companies are increasingly co-developing drug-device combination products, incorporating OBIs in clinical trials and commercialization plans. Regulatory bodies are encouraging such integrated development, recognizing the role of devices in improving therapy compliance. Additionally, payers and healthcare systems are supporting at-home administration to reduce hospitalization and infusion center costs. These trends are expanding the role of OBIs from niche biologics to broader chronic disease management.

What Factors Are Driving Growth in the On-Body Injectors Market?

Growth in the on-body injectors market is driven by several factors. Rising burden of chronic and lifestyle diseases is increasing demand for long-term drug delivery solutions. Advances in biologic formulations, including high-concentration and high-viscosity drugs, are driving need for wearable delivery platforms. Patient preference for self-administration and at-home treatment is accelerating adoption of OBIs, particularly in oncology, immunology, and endocrinology. Technological improvements in device design, safety, and digital integration are supporting regulatory approvals and market penetration. Additionally, healthcare cost pressures and the shift toward value-based care are encouraging pharmaceutical and device companies to invest in OBIs that reduce treatment complexity, improve adherence, and enhance patient quality of life. These factors collectively support strong momentum in wearable injector development and global market expansion.

SCOPE OF STUDY:

The report analyzes the On-Body Injectors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Electronic Injectors, Mechanical Injectors); Disease (Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease, Other Diseases); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AptarGroup Inc.
  • BD (Becton, Dickinson & Co.)
  • Coherus BioSciences, Inc.
  • Debiotech SA
  • E3D Elcam Drug Delivery Devices
  • Enable Injections
  • Gerresheimer AG
  • Insulet Corporation
  • LTS Lohmann Therapie-Systeme AG
  • Medtronic plc
  • Nemera
  • Roche (Accu-Chek)
  • Sanofi
  • ScPharmaceuticals (ScPharma)
  • Sensile Medical AG
  • SteadyMed Therapeutics
  • Stevanato Group
  • West Pharmaceutical Services, Inc.
  • Ypsomed AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • On-Body Injectors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Diseases Propels Demand for Self-Administered, Long-Acting Drug Delivery Devices
    • Shift Toward Home-Based Care Expands Addressable Market for Wearable and On-Body Injection Systems
    • Growth in Biologics and Large-Molecule Therapies Strengthens Business Case for On-Body Delivery Platforms
    • Increased Focus on Patient Adherence and Convenience Drives Adoption of Hands-Free Injection Devices
    • Advancements in Microelectronics and Battery Technologies Enhance Reliability and Portability of On-Body Injectors
    • Regulatory Support for Connected Health Solutions Spurs Development of Smart On-Body Devices with Monitoring Capabilities
    • Expansion of Subcutaneous Drug Formulations Generates Opportunities for Alternative to In-Clinic Infusion Therapy
    • Integration of Wireless Connectivity and App-Based Interfaces Promotes Real-Time Dose Tracking and Alerts
    • Rising Healthcare Costs and Workforce Shortages Accelerate Use of Automated Injection Systems to Reduce Hospital Dependence
    • Increase in FDA Approvals and CE Marking of Wearable Injectors Boosts Commercial Availability and Market Access
    • Patient-Centric Design Trends Spur Innovation in Painless, Low-Profile On-Body Injection Devices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World On-Body Injectors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for On-Body Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for On-Body Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Electronic Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Electronic Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Mechanical Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Mechanical Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diabetes Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Diabetes Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Neurological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Neurological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Immuno-Oncological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Immuno-Oncological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • JAPAN
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • CHINA
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • EUROPE
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for On-Body Injectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • FRANCE
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • GERMANY
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • UNITED KINGDOM
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • ASIA-PACIFIC
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030

IV. COMPETITION